FLJ45530 inhibitors are a class of small molecules that specifically target the FLJ45530 protein, a gene product associated with various cellular processes, including signaling pathways, gene expression, and cellular proliferation. These inhibitors are designed to modulate the activity of FLJ45530 by binding to critical sites on the protein, altering its conformation or functionality. By inhibiting the activity of FLJ45530, these compounds can disrupt downstream signaling cascades and biological processes that rely on this protein's proper function. This makes them valuable tools for investigating the biological roles of FLJ45530 in cellular and molecular research. These inhibitors are often employed in experiments to study protein interactions, post-translational modifications, and other biochemical events that are regulated by FLJ45530 in vitro and in cell-based systems.
Chemically, FLJ45530 inhibitors typically feature diverse structural scaffolds that allow for selective binding to specific domains of the FLJ45530 protein. These scaffolds often include heterocyclic cores, aromatic rings, and functional groups that engage in hydrogen bonding, van der Waals forces, or hydrophobic interactions with the protein. Structural optimization of these inhibitors is frequently performed to enhance their binding affinity, selectivity, and overall stability in biological systems. Researchers utilize these compounds to better understand the structural and functional characteristics of FLJ45530, as well as its broader role in various cellular contexts. Through the use of such inhibitors, scientists can dissect complex molecular pathways and gather detailed insights into how FLJ45530 contributes to critical cellular mechanisms.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that can non-selectively inhibit protein kinases possibly related to FLJ45530. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Inhibits DNA methyltransferases, potentially affecting gene expression of proteins including FLJ45530. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor, altering chromatin structure and possibly gene expression of FLJ45530. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can stabilize proteins and possibly alter degradation pathways involving FLJ45530. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
HSP90 inhibitor that can disrupt protein folding and may affect FLJ45530 client proteins. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Tyrosine kinase inhibitor that may affect signaling pathways in which FLJ45530 is involved. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK and may alter the MAPK/ERK pathway, potentially affecting FLJ45530's role within this pathway. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
Rac1 inhibitor that can alter actin cytoskeleton organization, potentially impacting FLJ45530's associated processes. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Inhibits the Hedgehog signaling pathway, which may intersect with signaling pathways involving FLJ45530. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
Glucose analog that inhibits glycolysis and can alter energy metabolism possibly related to FLJ45530. | ||||||